Skip to content

A multicenter clinical study of terlipressin in reducing ascites after hepatectomy

A multicenter clinical study of terlipressin in reducing ascites after hepatectomy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016000
Enrollment
Unknown
Registered
2018-05-05
Start date
2017-10-01
Completion date
Unknown
Last updated
2018-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic carcinoma

Interventions

1:Terlipressin + Routine treatment
2:Routine treatment without Terlipressin

Sponsors

Anhui Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Compliance with the criteria for hepatocellular carcinoma diagnosis of liver cancer in 2017 by the Ministry of Health; 2. Adult patients aged 18-70 years, regardless of gender; 3. General good condition, ASA grade I, Child grade A-B, adequate liver reserve function and residual liver volume; 4. The tumor meets the surgical indications and there are no surgical contraindications, including severe cardiovascular and cerebrovascular diseases, respiratory failure, mental disorders, etc.; 5. Proposed open abdominal hepatectomy; 6. Planned liver resection no more than half liver or 4 liver segments.

Exclusion criteria

Exclusion criteria: 1. Combines severe cardiovascular and cerebrovascular diseases, respiratory diseases, autoimmune diseases, and chronic renal insufficiency, and long-term use of immunosuppressants; 2. Relapsed tumor or patient's end-stage tumor is not suitable for surgery; 3. Biliary leakage after surgery; 4. People with severe metabolic, endocrine and hematological disorders; 5. Hepatic encephalopathy; 6. Patients with postoperative abdominal hemorrhage (>500ml); 7. Patients undergoing secondary surgery for bile leakage or bleeding; 8. Cholangiocellular carcinoma; 9. Benign tumor; 10. Incorporate other tumors; 11. This hospitalization combined with other surgery, or combined with other organs; 12. Has undergone major surgery in the past; 13. The patient or family member does not agree to participate in the study, or cannot understand it and cannot cooperate with the study; 14. Patients undergoing reoperation for recurrence of liver cancer.

Design outcomes

Primary

MeasureTime frame
ascites;

Secondary

MeasureTime frame
Postoperative hospital stay;

Countries

China

Contacts

Public ContactWeidong Jia

Anhui Provincial Hospital

jwd1968@sina.com+86 13855168588

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026